Vertex CEO Sold Stock Seven Days After Touting a Strong Quarter
As seen on the 24/7 Wall St. homepage on November 10, 2026.
Vertex delivered excellent third quarter results marked by strong revenue growth across the increasingly diversified portfolio, continued advancement of the R&D pipeline, and the successful close of the Crinetics Pharmaceuticals acquisition.
Seven days after that earnings call, Kewalramani filed a Form 4 showing she sold stock in the $138.9 billion drugmaker. Insider sales at the top often run on preset schedules, but selling into your own victory lap is worth logging before the next catalyst.
Continue ReadingShow less
Reshma Kewalramani's Form 4 filing landed one week after she called Vertex Pharmaceuticals' third quarter 'excellent,' giving investors tracking insider behavior at the $138.9 billion company a fresh data point to weigh against management's optimism.
On the same earnings call, she highlighted R&D pipeline advancement and the completed Crinetics Pharmaceuticals acquisition as markers of momentum.
Sponsored
Insider sales at large-cap pharmaceutical companies frequently run on preset 10b5-1 plans scheduled well in advance, so the filing is not by itself a signal about near-term price direction.
Keep an eye on the stock into the next pipeline readout, regulatory decision, or earnings report.
Sources
Mentioned: VRTX